BRPI0809996B8 - compounds, their uses to treat a proliferative, viral, neurodegenerative, CNS disorder, diabetes, alopecia and stroke, and pharmaceutical compositions - Google Patents
compounds, their uses to treat a proliferative, viral, neurodegenerative, CNS disorder, diabetes, alopecia and stroke, and pharmaceutical compositionsInfo
- Publication number
- BRPI0809996B8 BRPI0809996B8 BRPI0809996A BRPI0809996A BRPI0809996B8 BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8 BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- alopecia
- diabetes
- stroke
- viral
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 201000004384 Alopecia Diseases 0.000 title abstract 2
- 208000006011 Stroke Diseases 0.000 title abstract 2
- 231100000360 alopecia Toxicity 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000021245 head disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
compostos. a presente invenção refere-se a compostos de fórmula (i) em que: r1 e r2 são cada qual independentemente h, alquila ou haloalquila r3 e r4 são cada qual independentemente h, haloalquila ou arila; r5 é alquila ou cicloalquilaquila ou cicloalqui-alquila cada das quais pode ser opcionalmente substituída com um ou mais grupos oh, r6 é selecionado a partir de ciclopropilamino, ciclopropilmetilsmino, ciclobutilamino, ciclobutilmetialamino e fórmula (a) em que um dentre x,y,e z é n e os restantes saõ cr9, r7, r8 e cada são independentemente h alquila ou haloalquila, em que pelo menos um dentre r7, r8, e cada r9 é diferente de h.um outro aspectro da invenção refere-se ás composições farmacêuticas que compreendem compostos de fórmula (i) e o uso dos referidos compostos no tratamento de distúrbios proliferativos distúrbios virais, acidente vascular cerebral, alopecia, disturbios dos cns, distúrbios neurodegenerativos, ou diabetes.compounds. The present invention relates to compounds of formula (I) wherein: r1 and r2 are each independently h, alkyl or haloalkyl; r3 and r4 are each independently h, haloalkyl or aryl; r5 is alkyl or cycloalkylalkyl or cycloalkylalkyl each of which may be optionally substituted with one or more oh groups, r6 is selected from cyclopropylamino, cyclopropylmethylsmino, cyclobutylamino, cyclobutylmetalamino and formula (a) wherein one of x,y,ez is n and the remainder are cr9, r7, r8 and each are independently h alkyl or haloalkyl, wherein at least one of r7, r8, and each r9 is different from h. Another aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I) and the use of said compounds in the treatment of proliferative disorders, viral disorders, stroke, alopecia, head disorders, neurodegenerative disorders, or diabetes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92189707P | 2007-04-04 | 2007-04-04 | |
| GBGB0706632.7A GB0706632D0 (en) | 2007-04-04 | 2007-04-04 | New purine derivatives |
| PCT/GB2008/001173 WO2008122767A2 (en) | 2007-04-04 | 2008-04-02 | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0809996A2 BRPI0809996A2 (en) | 2014-10-14 |
| BRPI0809996B1 BRPI0809996B1 (en) | 2019-09-03 |
| BRPI0809996B8 true BRPI0809996B8 (en) | 2021-05-25 |
Family
ID=38090893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809996A BRPI0809996B8 (en) | 2007-04-04 | 2008-04-02 | compounds, their uses to treat a proliferative, viral, neurodegenerative, CNS disorder, diabetes, alopecia and stroke, and pharmaceutical compositions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8592581B2 (en) |
| EP (1) | EP2139893B1 (en) |
| JP (1) | JP5466145B2 (en) |
| CN (1) | CN101679434B (en) |
| AU (1) | AU2008235361B2 (en) |
| BR (1) | BRPI0809996B8 (en) |
| CA (1) | CA2681529C (en) |
| ES (1) | ES2427845T3 (en) |
| GB (1) | GB0706632D0 (en) |
| MX (1) | MX2009010660A (en) |
| PL (1) | PL2139893T3 (en) |
| RU (1) | RU2461559C2 (en) |
| WO (1) | WO2008122767A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0903346D0 (en) | 2009-02-27 | 2009-04-08 | Cambridge Advanced Tech | Transgenic Plants |
| GB201001075D0 (en) * | 2010-01-22 | 2010-03-10 | Cyclacel Ltd | Crystalline forms |
| DE102011111400A1 (en) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclic heteroaromatic compounds |
| US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
| MX2017009295A (en) | 2015-01-16 | 2018-03-07 | Massachusetts Gen Hospital | Compounds for improving mrna splicing. |
| JP6591036B2 (en) | 2016-02-26 | 2019-10-16 | 公益財団法人がん研究会 | Screening method and evaluation system of anticancer agent focusing on HP1 function |
| EP3573988B1 (en) | 2017-01-26 | 2022-12-28 | Cyclacel Limited | Process for preparing purine derivatives |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| WO2020093006A1 (en) | 2018-11-01 | 2020-05-07 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
| RU2754441C2 (en) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | New cdk8/19 inhibitors |
| GB202000901D0 (en) | 2020-01-22 | 2020-03-04 | Cyclacel Ltd | Process |
| JP2024519215A (en) | 2021-05-07 | 2024-05-09 | カイメラ セラピューティクス， インコーポレイテッド | CDK2 degraders and their uses |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741881B1 (en) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | NOVEL PURINE DERIVATIVES HAVING IN PARTICULAR ANTI-PROLIFERATIVE PRORIETES AND THEIR BIOLOGICAL APPLICATIONS |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| CZ27399A3 (en) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments |
| EP1150982B1 (en) * | 1999-02-01 | 2005-10-12 | Cv Therapeutics, Inc. | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha |
| US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| ATE301123T1 (en) * | 2001-06-27 | 2005-08-15 | Cyclacel Ltd | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| US6812232B2 (en) * | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| JP2006516561A (en) * | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 2-Aminopyridine substituted heterocycles as inhibitors of cell proliferation |
| AU2005276231A1 (en) * | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases |
| GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
-
2007
- 2007-04-04 GB GBGB0706632.7A patent/GB0706632D0/en not_active Ceased
-
2008
- 2008-04-02 RU RU2009140753/04A patent/RU2461559C2/en active
- 2008-04-02 PL PL08718980T patent/PL2139893T3/en unknown
- 2008-04-02 JP JP2010501585A patent/JP5466145B2/en active Active
- 2008-04-02 BR BRPI0809996A patent/BRPI0809996B8/en active IP Right Grant
- 2008-04-02 WO PCT/GB2008/001173 patent/WO2008122767A2/en not_active Ceased
- 2008-04-02 ES ES08718980T patent/ES2427845T3/en active Active
- 2008-04-02 CA CA2681529A patent/CA2681529C/en active Active
- 2008-04-02 MX MX2009010660A patent/MX2009010660A/en active IP Right Grant
- 2008-04-02 AU AU2008235361A patent/AU2008235361B2/en not_active Ceased
- 2008-04-02 EP EP08718980.9A patent/EP2139893B1/en active Active
- 2008-04-02 CN CN2008800189406A patent/CN101679434B/en active Active
-
2009
- 2009-10-05 US US12/573,337 patent/US8592581B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2461559C2 (en) | 2012-09-20 |
| US20100093769A1 (en) | 2010-04-15 |
| RU2009140753A (en) | 2011-05-10 |
| EP2139893B1 (en) | 2013-06-19 |
| HK1139939A1 (en) | 2010-09-30 |
| AU2008235361B2 (en) | 2013-02-14 |
| ES2427845T3 (en) | 2013-11-04 |
| PL2139893T3 (en) | 2013-11-29 |
| GB0706632D0 (en) | 2007-05-16 |
| CN101679434A (en) | 2010-03-24 |
| CN101679434B (en) | 2013-09-25 |
| EP2139893A2 (en) | 2010-01-06 |
| BRPI0809996A2 (en) | 2014-10-14 |
| AU2008235361A1 (en) | 2008-10-16 |
| JP2010523534A (en) | 2010-07-15 |
| US8592581B2 (en) | 2013-11-26 |
| CA2681529A1 (en) | 2008-10-16 |
| WO2008122767A3 (en) | 2008-12-31 |
| WO2008122767A2 (en) | 2008-10-16 |
| CA2681529C (en) | 2015-06-30 |
| JP5466145B2 (en) | 2014-04-09 |
| BRPI0809996B1 (en) | 2019-09-03 |
| MX2009010660A (en) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0809996B8 (en) | compounds, their uses to treat a proliferative, viral, neurodegenerative, CNS disorder, diabetes, alopecia and stroke, and pharmaceutical compositions | |
| BR112014023384A2 (en) | spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof | |
| BR112022021962A2 (en) | IMIDAZOPYRIDAZINES AS IL-17 MODULATORS | |
| BRPI0811280B8 (en) | amino-heterocyclic compounds, pharmaceutical composition comprising them and uses of said compounds | |
| AR056320A1 (en) | CHROMAN AND CHROME DERIVATIVES, OBTAINING PROCESSES, PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME | |
| BR112015028879A8 (en) | heterocyclic derivative compounds, pharmaceutical composition comprising said compounds and uses thereof | |
| BR112015025766A2 (en) | highly active nucleoside derivative for the treatment of hcv | |
| BR112014007193A2 (en) | pyrazoloquinolinone derivatives, their preparation and their therapeutic use | |
| BR112014011850A2 (en) | aminopyrimidine derivatives as lrrk2 modulators | |
| CL2008002271A1 (en) | (2s, 3r) -n- (2 - ((3-pyridinyl) methyl) -1-azabicyclo [2.2.2] oct-3-yl) benzofuran-2-carboxamide or its pharmaceutical salt; Preparation process; intermediary compounds; pharmaceutical composition comprising said compound; and use of the compound to treat a disorder of the central nervous system such as Alzheimer's, senile dementia, parkinson's. | |
| BR112015020772A2 (en) | pyrimidine and pyridine compounds and their use | |
| BR112014004465A2 (en) | compounds and compositions as pdgfr kinase inhibitors | |
| BR112013020620A2 (en) | 4-hydroxybutyric acid analogs | |
| BR112014000792A2 (en) | Piperidinyl Compounds for Use as Tanquirase Inhibitors | |
| BR112014004319A2 (en) | compounds and compositions as c-kit kinase inhibitors | |
| BR112015008717A2 (en) | compound, pharmaceutical composition, method of treating type II diabetes, use of the compound of formula (i), medication for treating type II diabetes | |
| BRPI0709773B8 (en) | malonamide derivatives, its production process, medicine, and its uses as gamma-secretase inhibitors in the treatment of alzheimer's disease | |
| EA201171172A1 (en) | APPLICATION IN THERAPY DERIVATIVES OF HINAZOLINDION | |
| BR112014012459A2 (en) | 2h-indazoles as ep2 receptor antagonists | |
| BRPI0513379A (en) | sulfonamide derivatives | |
| BR112015022849A2 (en) | nitroxoline base addition salts and uses thereof | |
| ECSP088257A (en) | AMIDA DERIVATIVES | |
| EA201070495A1 (en) | Γ-SECRETASE ACTIVITY MODULATORS FROM PIPERIDINYL AND PIPERASININIL GROUP | |
| BR112018004719A2 (en) | fluoroindole compound, pharmaceutical composition, method for treating a m1 muscarinic receptor-related disorder and use of the compound | |
| BR112014031969A2 (en) | pyrimidinone derivatives as antimalarial agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM |
|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |